Amino_NN Acid_NP Substitutions_NP at_IN Position_NP 69_CD of_IN the_DT Reverse_NP Transcriptase_NP of_IN Human_NP Immunodeficiency_NN Virus_NP Type_NP 1_CD Are_VBP Frequent_JJ in_IN Zalcitabine-Naive_NP Antiretroviral-Drug-Experienced_NP Patients_NPS 1_CD RT_NP )_) gene_NN affect_VB susceptibility_NN to_TO nucleoside-nucleotide_NN analog_JJ RT_NP inhibitors_NNS (_( NRTIs_NP )_) ._SENT While_IN it_PP is_VBZ classically_RB considered_VBN that_IN the_DT T69D/N_NP mutation_NN confers_VBZ resistance_NN to_TO zalcitabine_NP (_( dideoxycytidine_NP [_SYM ddC_NN ]_SYM )_) ,_, we_PP have_VBP demonstrated_VBN ,_, and_CC Winters_NP and_CC Merigan_NP have_VBP confirmed_VBN ,_, that_IN this_DT mutation_NN can_MD be_VB identified_VBN in_IN ddC-naive_JJ individuals_NNS ._SENT On_IN the_DT basis_NN of_IN this_DT observation_NN ,_, we_PP have_VBP further_JJR analyzed_VBD the_DT amino_NN acid_NN substitutions_NNS at_IN position_NN 69_CD in_IN the_DT RT_NP sequences_NNS obtained_VBD routinely_RB in_IN our_PP$ laboratory_NN ;_: amino_NN acid_NN insertions_NNS or_CC deletions_NNS at_IN this_DT position_NN have_VBP not_RB been_VBN considered_VBN in_IN this_DT study_NN ._SENT After_IN exclusion_NN of_IN the_DT patients_NNS tested_VBN after_IN treatment_NN interruption_NN ,_, 789_CD RT_NP sequences_NNS were_VBD available_JJ for_IN analysis_NN :_: 34_CD from_IN antiretroviral-naive_JJ patients_NNS and_CC 755_CD from_IN antiretroviral-experienced_JJ patients_NNS ._SENT Among_IN the_DT antiretroviral-experienced_JJ patients_NNS ,_, 50_CD (_( 6.6_CD %_NN )_) had_VBD received_VBN one_CD antiretroviral_JJ regimen_NN ,_, 444_CD (_( 58.8_CD %_NN )_) had_VBD received_VBN two_CD or_CC three_CD antiretroviral_JJ regimens_NNS ,_, and_CC 261_CD (_( 34.6_CD %_NN )_) had_VBD received_VBN four_CD or_CC more_JJR antiretroviral_JJ regimens_NNS ;_: 3_CD (_( 0.4_CD %_NN )_) had_VBD received_VBN one_CD NRTI_NP ,_, 58_CD (_( 7.7_CD %_NN )_) had_VBD received_VBN two_CD NRTIs_NP ,_, 89_CD (_( 11.8_CD %_NN )_) had_VBD received_VBN three_CD NRTIs_NP ,_, 221_CD (_( 29.3_CD %_NN )_) had_VBD received_VBN four_CD NRTIs_NP ,_, 235_CD (_( 31.1_CD %_NN )_) had_VBD received_VBN five_CD NRTIs_NP ,_, 145_CD (_( 19.2_CD %_NN )_) had_VBD received_VBN six_CD NRTIs_NP ,_, and_CC 4_CD (_( 0.5_CD %_NN )_) had_VBD received_VBN seven_CD NRTIs_NP ._SENT Amino_NN acid_NN substitutions_NNS at_IN position_NN 69_CD were_VBD not_RB found_VBN in_IN sequences_NNS from_IN the_DT NRTI-naive_JJ patients_NNS but_CC were_VBD found_VBN in_IN those_DT from_IN 116_CD (_( 15.4_CD %_NN )_) NRTI-experienced_JJ patients_NNS :_: 71_CD patient_NN sequences_NNS (_( 61.2_CD %_NN )_) had_VBD T69D_JJ mutations_NNS ,_, 28_CD (_( 24.1_CD %_NN )_) had_VBD T69N_NP mutations_NNS ,_, 7_CD (_( 6.0_CD %_NN )_) had_VBD T69S_NP mutations_NNS ,_, 4_CD (_( 3.4_CD %_NN )_) had_VBD T69A_NP mutations_NNS ,_, 3_LS (_( 2.6_CD %_NN )_) had_VBD T69E_JJ mutations_NNS ,_, and_CC 1_CD each_DT (_( 0.9_CD %_NN )_) had_VBD T69G_NP ,_, T69I_NP ,_, and_CC T69L_NP mutations_NNS ._SENT The_DT prevalence_NN of_IN amino_NN acid_NN substitutions_NNS at_IN position_NN 69_CD increased_VBN significantly_RB with_IN the_DT number_NN of_IN drug_NN regimens_NNS that_IN a_DT patient_NN received_VBN (_( P_NN =_SYM 0.0002_CD )_) ,_, since_IN a_DT prevalence_NN of_IN 8.0_CD %_NN was_VBD observed_VBN in_IN patients_NNS who_WP had_VBD received_VBN one_CD treatment_NN regimen_NN and_CC a_DT prevalence_NN of_IN 21.8_CD %_NN was_VBD observed_VBN in_IN patients_NNS who_WP had_VBD received_VBN four_CD or_CC more_JJR treatment_NN regimens_NNS ._SENT A_DT significant_JJ relationship_NN (_( P_NN =_SYM 0.01_CD )_) between_IN the_DT prevalence_NN of_IN amino_NN acid_NN substitutions_NNS at_IN position_NN 69_CD and_CC the_DT number_NN of_IN NRTIs_NP that_IN a_DT patient_NN received_VBD was_VBD also_RB observed_VBN ._SENT A_DT multivariate_JJ logistic-regression_NN analysis_NN showed_VBD that_IN the_DT number_NN of_IN antiretroviral_JJ drug_NN regimens_NNS that_IN a_DT patient_NN received_VBD was_VBD the_DT sole_JJ factor_NN independently_RB related_VBN to_TO amino_NN acid_NN substitutions_NNS at_IN position_NN 69_CD ._SENT However_RB ,_, when_WRB only_RB the_DT D_NP and_CC N_NP substitutions_NNS were_VBD considered_VBN ,_, a_DT significant_JJ relationship_NN (_( P_NN =_SYM 0.03_CD )_) between_IN the_DT T69D/N_NP mutation_NN and_CC experience_NN with_IN didanosine_NN (_( ddI_NNS )_) was_VBD observed_VBN (_( data_NNS not_RB shown_VBN )_) ._SENT There_EX was_VBD no_DT significant_JJ relationship_NN between_IN D/N_NP (_( P_NN =_SYM 0.26_CD )_) or_CC other_JJ amino_NN acid_NN substitutions_NNS (_( P_NN =_SYM 0.13_CD )_) at_IN position_NN 69_CD and_CC experience_NN with_IN ddC_NN ._SENT By_IN univariate_JJ analysis_NN ,_, amino_NN acid_NN substitutions_NNS at_IN position_NN 69_CD were_VBD significantly_RB associated_VBN with_IN mutations_NNS at_IN positions_NNS 44_CD ,_, 67_CD ,_, 70_CD ,_, 118_CD ,_, 210_CD ,_, 215_CD ,_, and_CC 219_CD ,_, whereas_IN a_DT borderline_JJ significance_NN was_VBD observed_VBN for_IN the_DT association_NN with_IN the_DT L74V_NP mutation_NN ._SENT By_IN multivariate_JJ analysis_NN ,_, however_RB ,_, only_RB E44D/A_NP (_( P_NN =_SYM 0.02_CD )_) ,_, D67N_NP (_( P_NN <_0.0001), D_NP and_CC T->N_NP )_) are_VBP common_JJ in_IN multi-NRTI-experienced_JJ patients_NNS ,_, that_IN the_DT prevalence_NN of_IN these_DT mutations_NNS increases_NNS with_IN the_DT number_NN of_IN NRTI_NP combination_NN regimens_NNS received_VBD ,_, and_CC that_IN previous_JJ ddI_NNS rather_RB than_IN ddC_NN experience_NN could_MD be_VB a_DT factor_NN of_IN selection_NN of_IN the_DT T69D/N_NP mutations_NNS in_IN multi-NRTI-treated_JJ pa-tients_NNS ._SENT These_DT conditions_NNS of_IN selection_NN are_VBP also_RB supported_VBN by_IN the_DT association_NN observed_VBD between_IN amino_NN acid_NN substitutions_NNS at_IN position_NN 69_CD and_CC the_DT E44A/D_NN ,_, V118I_NP ,_, and_CC Q151M_NP mutations_NNS ,_, which_WDT are_VBP also_RB known_VBN to_TO be_VB associated_VBN with_IN multiple_JJ NRTI_NP experience_NN ,_, including_VBG experience_NN with_IN ddI_NN ._SENT Amino_NN acid_NN substitutions_NNS were_VBD also_RB closely_RB associated_VBN with_IN the_DT D67N_NP mutation_NN ,_, which_WDT is_VBZ located_VBN in_IN the_DT same_JJ beta3-beta4_NN hairpin_NN loop_NN (_( positions_NNS 67_CD to_TO 70_CD )_) region_NN of_IN the_DT RT_NP ;_: this_DT association_NN suggests_VBZ that_IN interactions_NNS exist_VBP between_IN these_DT mutations_NNS ._SENT Our_PP$ results_NNS ,_, in_IN agreement_NN with_IN those_DT reported_VBN by_IN Winters_NP and_CC Merigan_NP ,_, indicate_VBP that_IN amino_NN acid_NN substitutions_NNS at_IN position_NN 69_CD may_MD be_VB selected_VBN for_IN by_IN ddC-free_JJ antiretroviral_JJ regimens_NNS ._SENT These_DT mutations_NNS could_MD therefore_RB be_VB involved_VBN in_IN resistance_NN to_TO NRTIs_NP other_JJ than_IN ddC_NN ._SENT This_DT is_VBZ supported_VBN by_IN the_DT findings_NNS of_IN Winters_NP and_CC Merigan_NP that_WDT show_VBP that_IN different_JJ substitutions_NNS at_IN position_NN 69_CD confer_VBP reduced_VBN susceptibility_NN to_TO zidovudine_NP ,_, ddI_NP ,_, and_CC stavudine_NP ._SENT The_DT T69D/N_NP mutation_NN is_VBZ currently_RB taken_VBN into_IN consideration_NN for_IN interpreting_VBG resistance_NN to_TO ddI_NNS (_( low-level_JJ resistance_NN )_) and_CC stavudine_NP (_( potential_JJ low-level_JJ resistance_NN )_) by_IN using_VBG the_DT Stanford_NP HIV_NP RT_NP and_CC protease_NN sequence_NN database_NN algorithm_NN ._SENT However_RB ,_, more_JJR effort_NN is_VBZ needed_VBN to_TO accurately_RB interpret_VB HIV-1_JJ genotypes_NNS that_WDT encode_VBP amino_NN acid_NN sub-stitutions_NNS at_IN position_NN 69_CD ._SENT In_IN particular_JJ ,_, the_DT effect_NN of_IN the_DT different_JJ amino_NN acid_NN substitutions_NNS at_IN this_DT position_NN and_CC the_DT interactions_NNS of_IN these_DT substitutions_NNS with_IN the_DT other_JJ NRTI_NP resistance-associated_JJ mutations_NNS remain_VBP poorly_RB documented_VBN ._SENT TABLE_NN 1_CD :_: Association_NN of_IN the_DT amino_NN acid_NN substitutions_NNS at_IN position_NN 69_CD with_IN other_JJ NRTI_NP resistance_NN mutations_NNS in_IN 789_CD sequences_NNS 